MLICM
PBYI icon

Metropolitan Life Insurance Company (MetLife)’s Puma Biotechnology PBYI Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-7,892
Closed -$76.7K – 2830
2021
Q1 		$76.7K Sell
7,892
-1,563
-17% -$17.5K ﹤0.01% 2483
2020
Q4 		$97K Hold
9,455
– – ﹤0.01% 2372
2020
Q3 		$95.4K Sell
9,455
-269
-3% -$2.74K ﹤0.01% 2245
2020
Q2 		$101K Hold
9,724
– – ﹤0.01% 2250
2020
Q1 		$82.1K Buy
9,724
+85
+0.9% +$826 ﹤0.01% 2158
2019
Q4 		$84.3K Sell
9,639
-976
-9% -$8.08K ﹤0.01% 2418
2019
Q3 		$114K Buy
10,615
+1,305
+14% +$14.1K ﹤0.01% 2227
2019
Q2 		$118K Hold
9,310
– – ﹤0.01% 2219
2019
Q1 		$361K Sell
9,310
-388
-4% -$11.8K 0.01% 1506
2018
Q4 		$197K Buy
9,698
+374
+4% +$11.2K ﹤0.01% 1829
2018
Q3 		$428K Hold
9,324
– – 0.01% 1483
2018
Q2 		$552K Hold
9,324
– – 0.01% 1253
2018
Q1 		$634K Buy
9,324
+138
+2% +$10.3K 0.01% 1124
2017
Q4 		$908K Sell
9,186
-10,440
-53% -$1.17M 0.01% 944
2017
Q3 		$2.35M Sell
19,626
-159
-0.8% -$14.8K 0.01% 888
2017
Q2 		$1.73M Sell
19,785
-357
-2% -$20K 0.01% 993
2017
Q1 		$749K Hold
20,142
– – 0.01% 1387
2016
Q4 		$618K Buy
20,142
+2,247
+13% +$97.2K ﹤0.01% 1601
2016
Q3 		$1.2M Sell
17,895
-476
-3% -$24.1K 0.01% 1188
2016
Q2 		$547K Buy
18,371
+16,496
+880% +$516K ﹤0.01% 1630
2016
Q1 		$55K Hold
1,875
– – ﹤0.01% 2460
2015
Q4 		$147K Buy
1,875
+50
+3% +$3.92K ﹤0.01% 2442
2015
Q3 		$138K Hold
1,825
– – ﹤0.01% 2515
2015
Q2 		$213K Sell
1,825
-16,950
-90% -$3.07M ﹤0.01% 2361
2015
Q1 		$4.43M Buy
18,775
+970
+5% +$207K 0.03% 583
2014
Q4 		$3.37M Hold
17,805
– – 0.02% 725
2014
Q3 		$4.25M Sell
17,805
-750
-4% -$154K 0.03% 587
2014
Q2 		$1.23M Hold
18,555
– – 0.01% 1227
2014
Q1 		$1.93M Buy
18,555
+729
+4% +$85.7K 0.01% 1002
2013
Q4 		$1.85M Buy
17,826
+1,019
+6% +$59.8K 0.01% 1016
2013
Q3 		$902K Sell
16,807
-2,456
-13% -$132K 0.01% 1339
2013
Q2 		$855K Buy
+19,263
New +$679K 0.01% 1333

Other funds holding PBYI

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s PBYI Position: Q2 2021 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Puma Biotechnology (PBYI) in Q2 2021, closing a stake of 7,892 shares — an estimated $76.7K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in PBYI in Q2 2013 and held it in 32 quarters. The position peaked at $4.43M in Q1 2015. 120 funds tracked by Wall St. Rank hold PBYI as of Q2 2021.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Puma Biotechnology position as of Q2 2021 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 7,892 Puma Biotechnology shares in Q2 2021, an estimated $76.7K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Puma Biotechnology in Q2 2013 and held it in 32 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Puma Biotechnology position peaked at $4.43M in Q1 2015.
  • 120 funds tracked by Wall St. Rank held Puma Biotechnology as of Q2 2021.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2021, filed 16 Aug 2021.